Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Neoplasms 2Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Hemangioma 1Disease 1Carcinoma, Renal Cell 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasms × Urine Specimen Collection × Clear all
NCT02807129 2026-01-21

AgElOn

CHU de Reims

Phase NA Completed
296 enrolled
Tumor-Agnostic

Neoplasms

NCT05151341 2025-07-24

URODX-FGFR3

Institut de Cancérologie de Lorraine

Phase NA Completed
190 enrolled
Genitourinary

Urinary Bladder Neoplasms, Disease, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡